Search Results - "Katz, Matthew H"

Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma by Perri, Giampaolo, Prakash, Laura, Qiao, Wei, Varadhachary, Gauri R, Wolff, Robert, Fogelman, David, Overman, Michael, Pant, Shubham, Javle, Milind, Koay, Eugene J, Herman, Joseph, Kim, Michael, Ikoma, Naruhiko, Tzeng, Ching-Wei, Lee, Jeffrey E, Katz, Matthew H G

“…Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel (GA) are first-line…”
Get more information

Neoadjuvant therapy for pancreatic cancer by Springfeld, Christoph, Ferrone, Cristina R., Katz, Matthew H. G., Philip, Philip A., Hong, Theodore S., Hackert, Thilo, Büchler, Markus W., Neoptolemos, John

“…Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with surgical resection of the primary tumour and systemic chemotherapy, which…”
Get full text

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101 by Katz, Matthew H G, Shi, Qian, Ahmad, Syed A, Herman, Joseph M, Marsh, Robert de W, Collisson, Eric, Schwartz, Lawrence, Frankel, Wendy, Martin, Robert, Conway, William, Truty, Mark, Kindler, Hedy, Lowy, Andrew M, Bekaii-Saab, Tanios, Philip, Philip, Talamonti, Mark, Cardin, Dana, LoConte, Noelle, Shen, Perry, Hoffman, John P, Venook, Alan P

“…Although consensus statements support the preoperative treatment of borderline resectable pancreatic cancer, no prospective, quality-controlled, multicenter…”
Get more information

Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design by Katz, Matthew H. G., Marsh, Robert, Herman, Joseph M., Shi, Qian, Collison, Eric, Venook, Alan P., Kindler, Hedy L., Alberts, Steven R., Philip, Philip, Lowy, Andrew M., Pisters, Peter W. T., Posner, Mitchell C., Berlin, Jordan D., Ahmad, Syed A.

“…Background Methodological limitations of prior studies have prevented progress in the treatment of patients with borderline resectable pancreatic…”
Get full text

Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression by Bernard, Vincent, Semaan, Alexander, Huang, Jonathan, San Lucas, F Anthony, Mulu, Feven C, Stephens, Bret M, Guerrero, Paola A, Huang, Yanqing, Zhao, Jun, Kamyabi, Nabiollah, Sen, Subrata, Scheet, Paul A, Taniguchi, Cullen M, Kim, Michael P, Tzeng, Ching-Wei, Katz, Matthew H, Singhi, Aatur D, Maitra, Anirban, Alvarez, Hector A

“…Early detection of pancreatic ductal adenocarcinoma (PDAC) remains elusive. Precursor lesions of PDAC, specifically intraductal papillary mucinous neoplasms…”
Get full text

Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3–5.8 by Katz, Matthew H. G., Francescatti, Amanda B., Hunt, Kelly K.

“…Clinical practice guidelines in oncology have typically focused on workup, disease staging, and medical management. Although recommendations for surgical care…”
Get full text

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial by Katz, Matthew H G, Shi, Qian, Meyers, Jeff, Herman, Joseph M, Chuong, Michael, Wolpin, Brian M, Ahmad, Syed, Marsh, Robert, Schwartz, Larry, Behr, Spencer, Frankel, Wendy L, Collisson, Eric, Leenstra, James, Williams, Terence M, Vaccaro, Gina, Venook, Alan, Meyerhardt, Jeffrey A, O'Reilly, Eileen M

“…National guidelines endorse treatment with neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy…”
Get more information

Operative Standards for Cancer Care: One Step at a Time by Francescatti, Amanda B., Hieken, Tina J., Katz, Matthew H. G.

Get full text

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators by Katz, Matthew H. G., Fleming, Jason B., Bhosale, Priya, Varadhachary, Gauri, Lee, Jeffrey E., Wolff, Robert, Wang, Huamin, Abbruzzese, James, Pisters, Peter W. T., Vauthey, Jean‐Nicolas, Charnsangavej, Chusilp, Tamm, Eric, Crane, Christopher H., Balachandran, Aparna

“…BACKGROUND: Experience with preoperative therapy for other cancers has led to an assumption that borderline resectable pancreatic cancers can be converted to…”
Get full text

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas by Katz, Matthew H G, Ou, Fang-Shu, Herman, Joseph M, Ahmad, Syed A, Wolpin, Brian, Marsh, Robert, Behr, Spencer, Shi, Qian, Chuong, Michael, Schwartz, Lawrence H, Frankel, Wendy, Collisson, Eric, Koay, Eugene J, Hubbard, JoLeen M, Leenstra, James L, Meyerhardt, Jeffrey, O'Reilly, Eileen

“…Borderline resectable pancreatic cancers infiltrate into adjacent vascular structures to an extent that makes an R0 resection unlikely when pancreatectomy is…”
Get full text

The Landmark Series: Preoperative Therapy for Pancreatic Cancer by Patel, Sameer H., Katz, Matthew H. G., Ahmad, Syed A.

“…The surgical treatment of pancreas ductal adenocarcinoma (PDAC) is plagued by high rates of distant recurrences despite complete resection, highlighting the…”
Get full text

Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why? by Maxwell, Jessica E., Katz, Matthew H. G.

“…The role of (chemo) radiation in the perioperative management of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma is…”
Get full text

Thumbprinting Locally Advanced Pancreatic Cancer: Have We Developed the Optimal Staging System? by Hester, Caitlin A., Katz, Matthew H. G.

Get full text

Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation by Krishnan, Sunil, MD, Chadha, Awalpreet S., MD, Suh, Yelin, PhD, Chen, Hsiang-Chun, PhD, Rao, Arvind, PhD, Das, Prajnan, MD, Minsky, Bruce D., MD, Mahmood, Usama, MD, Delclos, Marc E., MD, Sawakuchi, Gabriel O., PhD, Beddar, Sam, PhD, Katz, Matthew H., MD, Fleming, Jason B., MD, Javle, Milind M., MD, Varadhachary, Gauri R., MD, Wolff, Robert A., MD, Crane, Christopher H., MD

“…Purpose To review outcomes of locally advanced pancreatic cancer (LAPC) patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with…”
Get full text

Shifting the Focus: Value-Based Care in Surgical Oncology by Allen, Casey J., Johnson, Fabian M., In, Haejin, Katz, Matthew H. G., Snyder, Rebecca A.

Get full text

Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review by Mavros, Michail N, Moris, Dimitrios, Karanicolas, Paul J, Katz, Matthew H G, O'Reilly, Eileen M, Pawlik, Timothy M

“…Adjuvant chemotherapy is the standard of care for resected pancreatic ductal adenocarcinoma (PDAC) based on level 1 evidence, but some studies suggest that a…”
Get more information

Neoadjuvant Chemotherapy in Pancreatic Cancer-Reply by Perri, Giampaolo, Katz, Matthew H G

Get more information

ASO Author Reflections: Technical Standards for Cancer Surgery: From “How I Do It” to “How We Do It” by Francescatti, Amanda B., Hunt, Kelly K., Katz, Matthew H. G.

Get full text

What Defines the Value of Minimally Invasive Surgery for Cancer Patients? by Hirata, Yuki, Lyu, Heather, Smith, Grace Li, Wang, Xin Shelley, Tran Cao, Hop S., Katz, Matthew H. G., Ikoma, Naruhiko

Get full text

ASO Author Reflections: It is Time to Prioritize Exercise in Pancreatic Cancer Survivorship by Parker, Nathan H., Katz, Matthew H. G.

Get full text